|
 |
| |
 |
|
|
|
|
| |
management team
|
|
 |
Emil D. Kakkis, M.D., Ph.D. |
|
| |
Chief Medical Officer
Dr. Kakkis joined BioMarin in September 1998 and
currently serves as chief medical officer. Together
with his colleague Elizabeth F. Neufeld, Ph.D.,
of the University of California at Los Angeles (UCLA),
Dr. Kakkis discovered how to produce a recombinant
form of alpha-L-iduronidase (later to become known
as Aldurazyme® [laronidase]), the enzyme which
people with mucopolysaccharidosis I (MPS I) are
lacking. Prior to BioMarin, Dr. Kakkis was an assistant
professor at the Harbor-UCLA Medical Center, Division
of Genetics, Department of Pediatrics. From 1991
to 1994, he was a fellow at the UCLA Intercampus
Medical Genetics training program after having conducted
his pediatric residency at the Harbor-UCLA Medical
Center. Dr. Kakkis is the author of numerous published
articles and abstracts on MPS I and alpha-L-iduronidase.
He holds an M.D. and a Ph.D. in biological chemistry
from the medical scientist training program at the
UCLA School of Medicine. He is board-certified in
pediatrics and medical genetics. |
|
| |
|
|
|
|
|
